November 22, 2018 | Campus
Banting painting of lab where insulin was discovered sells for 10 times more than expected
By Heidi Singer
U of T had hoped to purchase the painting sold at auction Wednesday night, but a determined buyer paid $313,250 for the artwork (photo by Geoffrey Vendeville)
Heffel Fine Art Auction House pledges its $53,250 commission to diabetes research at U of T
Sir Frederick Banting’s only known painting of the lab where he discovered insulin was sold at auction Wednesday for ten times its expected value. And fittingly, a portion of the sale price will go toward funding advances in diabetes research at the University of Toronto – just down the street from where the world-changing discovery was made almost a century ago.
Banting (BMed 1916, MD 1922, Hon PhD 1923) created the painting, called simply The Lab, in 1925. Although an accomplished painter of landscapes, he rarely chose his scientific work as a subject.
Twenty bidders competed for the historic work, including U of T, but a determined mystery buyer outbid the University in the end, paying $313,250 for the artwork over the telephone. To honour the painting’s subject and Banting’s legacy, Heffel Fine Art Auction House has pledged its commission of $53,250 to diabetes research at U of T.
“It is a privilege to be able to make this donation to the Banting & Best Diabetes Centre,” said Heffel’s Rebecca Rykiss. “At our auction previews across the country, we heard from countless enthusiasts, collectors and many affected by the disease just how meaningful this painting is. It’s not often that we have such a historically important work consigned to us and we are thrilled to honour the Nobel Prize winning scientist and his significant artistic career in this way.”
Several philanthropists had pledged to help U of T buy the painting so that it could be part of the upcoming centennial anniversary of the discovery of insulin. But the eventual winner appeared very determined to acquire the painting, said Professor Scott Mabury, U of T’s vice-president, university operations and vice-provost, academic operations.
“We were quite disappointed,” he said. “We tried. We gave it a great effort. Still, I hope in the fullness of time this painting will find its way into the 2021 celebrations of the discovery of insulin at U of T.”
How U of T diabetes researchers are furthering Banting's legacy
The donation will further Banting’s legacy at U of T, where diabetes researchers like Maria Cristina Nostro are using techniques nobody could have envisioned in the early 20th century to create a goal that seems futuristic even today.
Toronto is home to robust research communities in both diabetes and stem cell research. Nostro straddles both fields in her quest to regenerate the pancreas, or at least its function. She is part of a worldwide cohort of scientists engineering stem cells to cure type 1 diabetes.
A native of Italy, Nostro was completing a post-doctoral fellowship in New York, studying stem-cell biology, when her supervisor, Professor Gordon Keller, was recruited to Toronto to lead the McEwen Centre for Regenerative Medicine. She soon found herself in the city where both insulin and stem cells were discovered.
“Toronto is a great place to do research on diabetes and stem cells,” says Nostro (pictured left). “With the huge legacy from insulin, we have the Banting & Best Diabetes Centre that’s connecting all the scientists doing diabetes research in the city. And there’s so much going on with stem cell research. It’s a perfect match.”
“If we can do that, we can cure diabetes”
People with type 1 diabetes lack pancreatic beta cells, which play the crucial role of detecting sugar in the blood and signalling for the release of insulin. In the early 2000s, diabetes researchers first began experimenting with embryonic stem cells, which can potentially be turned into the cells associated with any organ. So far, scientists have used stem cells to create “immature” beta cells, which aren’t fully functional – but become more functional when placed in an animal’s body. As a result of this success, the first human trials with stem-cell derived pancreatic cells are now being conducted.
With human trials, there will be a need for more, and better functioning, pancreatic cells. Nostro and her team have made a major contribution to the process of creating them.
“We were among the first labs to understand how to efficiently create pancreatic cells,” she says. “And we’re collaborating with other Toronto scientists to find the best way to transplant the cells, making sure they’re not destroyed by the immune system and that they’re properly nourished right away by the body so they survive.”
Nostro is optimistic about improving treatment for type 1 diabetes in her lifetime.
“We need to be better than insulin,” she says. “We need something very safe and long-lasting. The beauty of regenerative medicine in diabetes is that we don’t have to recreate the entire pancreas. In type 1 diabetes, the pancreas works fine. We need to replenish the beta cells. If we can do that, we can cure diabetes.”